EUVIMEDEUVIMED entdecken
Crossref

Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program

M B Ba, F Giudici, C Bellini, G Auzac, G Louvel, S Bockel, Y Moukasse, I Chaffai, K Berthelot, A Vatonne, A Conversano, A Viansone und 5 weitere

Clinical Oncology · 2024-09 · 36 (9) · e333-e341

DOI: 10.1016/j.clon.2024.06.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2024-09. Verfasst von M B Ba und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Radiation Therapy Department, F-94805, Villejuif, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Feasibility Studies, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: FAST-Forward and UK-FAST-trials have demonstrated the safety and efficacy of five-fraction breast adjuvant radiation therapy (RT) and have become the standard of care for selected early breast cancer patients. In response to the additional burden caused by the COVID-19 pandemic, we implemented "One-Week Breast RT," an innovative program delivering five-fraction whole breast RT in a complete 5-day workflow. The primary objective of this study was to demonstrate the feasibility and safety of our program. The secondary objective was to evaluate cosmetic results. MATERIAL AND METHODS: A total of 120 patients treated from February 2021 to March 2022, received whole breast RT without lymph node irradiation nor boost, with 26 Gy in five fractions over one week. Inverse planning with restricted optimization parameters offers systematic deep inspiration breath-hold aimed to provide treatment plans compliant with FAST-Forward recommendations. Toxicity and cosmetic evaluations were prospectively registered prior (pre-RT), at the end (end-RT), and 6 months after RT (6 months) based on Common Terminology Criteria for Adverse Events v. 4.03 and Harvard scale. RESULTS: With a median age of 70 years (interquartile range (IQR): 66-74) and a median follow-up of 6 months (IQR: 6.01-6.25), most patients (93.3%) completed their RT in one week from baseline to the end of the treatment consultation. The most common acute toxicities (at end-RT) were skin-related: radio-dermatitis (72%), induration (35%), hyperpigmentation (8%), and breast edema (16%). The rate of radio-dermatitis decreased from end-RT to 6 months (71.7% vs 5.4%, P< 0.001). No patient experienced grade ≥3 toxicity. At 6 months, cosmetic results were generally good or excellent (94.1%). CONCLUSION: This study confirms the feasibility and acute safety of the "One-Week Breast RT" in real life. Favorable toxicity profiles and good cosmetic outcomes are in line with FAST-Forward results. A prospective national cohort, aimed at decreasing treatment burden, maintaining safety, efficacy, and improving RT workflow efficiency with longer follow-up is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFeasibility StudiesCOVID-19HumansFemaleAgedRadiotherapy, AdjuvantDose Fractionation, RadiationMiddle AgedProspective StudiesSARS-CoV-2Radiodermatitis

Stichwörter der Autor:innen

Acute toxicitiesearly breast cancerhypofractionated radiation therapyintensity modulated radiation therapyprospective cohortreal life data

Autor:innen und Institutionen

  • Gustave Roussy, Radiation Therapy Department, F-94805, Villejuif, France.
  • Bureau de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, F-94805, Villejuif, France.
  • Gustave Roussy, Surgery Department, F-94805, Villejuif, France.
  • Gustave Roussy, Medical Oncology Department, F-94805, Villejuif, France.
  • Gustave Roussy, Radiation Therapy Department, F-94805, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Inserm 1030, 94805, Villejuif, France.
  • Gustave Roussy, Radiation Therapy Department, F-94805, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Inserm 1030, 94805, Villejuif, France. Electronic address: sofia.rivera@gustaveroussy.fr.

Zitieren

APA

Ba, M. B., Giudici, F., Bellini, C., Auzac, G., Louvel, G., Bockel, S., Moukasse, Y., Chaffai, I., Berthelot, K., Vatonne, A., Conversano, A., Viansone, A., Larue, C., Deutsch, E., Michiels, S., Milewski, C., & Rivera, S. (2024). Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program. Clinical Oncology, 36(9), e333-e341. https://doi.org/10.1016/j.clon.2024.06.045

Vancouver

Ba MB, Giudici F, Bellini C, Auzac G, Louvel G, Bockel S, et al. Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program. Clinical Oncology. 2024;36(9):e333-e341. doi:10.1016/j.clon.2024.06.045

BibTeX
@article{Ba2024,
  author = {Ba, M B and Giudici, F and Bellini, C and Auzac, G and Louvel, G and Bockel, S and Moukasse, Y and Chaffai, I and Berthelot, K and Vatonne, A and Conversano, A and Viansone, A and Larue, C and Deutsch, E and Michiels, S and Milewski, C and Rivera, S},
  title = {Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program},
  journal = {Clinical Oncology},
  year = {2024},
  volume = {36},
  number = {9},
  pages = {e333--e341},
  doi = {10.1016/j.clon.2024.06.045}
}
Kostenlos starten →